Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving
Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.
You may also be interested in...
Amgen has revealed a significant – albeit expected – drop in second-quarter sales figures for its Amjevita US biosimilar rival to Humira.
Coherus has made deals with numerous pharmacy benefit managers and pharmacies to bring its low list price Yusimry adalimumab biosimilar to patients, as analysts continue to back Humira originator AbbVie as market leader.
In a busy couple of weeks for Biocon’s biosimilars unit, the firm has completed the “first wave” of integration for the business it acquired from Viatris, while also launching its US adalimumab biosimilar amid heavy competition.